Related Experiment Video
Updated: Apr 12, 2026

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells
Published on: November 21, 2025
Electrolyte disturbances and acute kidney injury induced by imatinib therapy
Rodrigo Azevedo de Oliveira1, Igor Denizarde Bacelar Marques1, Antonio Carlos Seguro1
1Department of Nephrology , University of São Paulo School of Medicine , São Paulo , Brazil.
Abstract:
Imatinib mesylate is an anticancer agent that selectively inhibits protein kinases involved in the pathophysiology of cancer. It is now the first-line therapy for patients with chronic myeloid leukaemia (CML) and is generally well tolerated. Here, we describe a case of a patient receiving imatinib for CML. The patient developed renal failure accompanied by severe hypophosphataemia, hypokalaemia and hypomagnesaemia. We discuss the pathophysiological characteristics of imatinib-induced renal injury, and we demonstrate that these electrolyte disturbances were caused by increased urinary excretion of phosphate and potassium. Early diagnosis and correction of imatinib-induced renal injury and electrolyte disorders can improve clinical outcomes.
Insights
Imatinib mesylate, used for chronic myeloid leukaemia (CML), can cause renal failure with severe electrolyte imbalances. Increased urinary phosphate and potassium excretion are key factors, necessitating early diagnosis and treatment.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Imatinib mesylate is a targeted therapy for chronic myeloid leukaemia (CML).
- While generally well-tolerated, imatinib can cause adverse effects.
- Renal complications and electrolyte disturbances are potential side effects.
Purpose of the Study:
- To report a case of imatinib-induced renal failure with severe hypophosphataemia, hypokalaemia, and hypomagnesaemia.
- To elucidate the pathophysiological mechanisms of imatinib-induced renal injury.
- To highlight the importance of early diagnosis and management of these complications.
Main Methods:
- Case report of a CML patient treated with imatinib.
- Analysis of renal function and serum/urine electrolytes.
- Review of literature on imatinib-induced nephrotoxicity.
Main Results:
- The patient developed acute renal failure with significant electrolyte abnormalities.
- Increased urinary excretion of phosphate and potassium was identified as the cause.
- Imatinib-induced renal injury was confirmed as the underlying pathology.
Conclusions:
- Imatinib mesylate can precipitate severe renal injury and electrolyte disorders.
- Increased urinary phosphate and potassium loss are critical pathophysiological mechanisms.
- Prompt recognition and management of these adverse effects are crucial for patient outcomes.
More Related Videos
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury I: Introduction
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology